Shots:
- AstraZeneca presented data at the ACC’25 and simultaneously published data in JACC from the PURSUIT P-IIb study (n=480) evaluating the efficacy, safety, and tolerability of AZD0780 (1mg, 3mg, 10mg & 30mg QD) added to SoC statin therapy vs PBO in dyslipidemic patients with LDL-C levels ≥70 and <190 mg/dL on moderate or high intensity statins, with or without ezetimibe
- In the study, n=426 started treatment, QD AZD0780 30mg with SoC reduced LDL-C by 50.7% at 12 weeks, regardless of baseline statin intensity. Furthermore, AZD0780 achieved LDL-C target (<70 mg/dL) in 84% of participants, vs 13% on statin therapy alone, based on AHA/ACC guidelines
- AZD0780 was well tolerated, and data from PURSUIT are consistent with P-I findings presented at the EAS’24
Ref: AstraZeneca | Image: AstraZeneca
Related News:- AstraZeneca’s Calquence (Acalabrutinib) Plus Chemoimmunotherapy Receives the CHMP’s Positive Opinion for 1L Mantle Cell Lymphoma (MCL)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
